文稿:傲雪
图片:网络
翻译:Tiffany
编辑:Tiffany
11月5日新西兰卫生部消息，新西兰政府表示，将另一种药物添加到新西兰的新冠肺炎药物套装中，对病人和卫生系统都是个好消息。
卫生部长安德鲁·利特尔(Andrew Little)说：“首先，通过接种疫苗、保持社交距离和戴口罩，防止人们感染新冠肺炎，仍然是对人们的最好保护，也是让那些需要它的人保持卫生系统自由的最佳保障。但我们需要治疗那些确实生病的人的药品，这就是为什么我非常高兴的是，国家药品采购机构制药公司已经获得了另一种药品的供应证明，可以对抗新冠肺炎病毒。巴里西尼是制药公司获得的第五种药物，它与雷莫司韦、托西利单抗、莫尔努皮雷韦和罗纳普雷夫并列的，因为医生可以为有一系列新冠肺炎症状的人提供治疗，巴利西尼也可以用来治疗重病患者，因为它可以减轻症状的严重程度，缩短住院时间，降低死亡的可能性”
卫生部长说：“制药公司预计这个月将收到500剂巴利西尼，这是很重要的，因为全球都缺乏托西利单抗，这给了临床医生另一种选择。”
所有五种药品的资金将来自政府的新冠肺炎基金。对新冠肺炎的使用还有待美泰西姆批准，但根据“药品法”第25条，临床医生将能够立即使用。
5 November，NZ secures another COVID-19 medicine
The addition of another drug to the suite of COVID-19 medicines available in New Zealand is good news for patients and for the health system, the Government says.
“Preventing people from getting COVID-19 in the first place, through vaccinations, social distancing and mask-wearing, is still the best protection for people and for keeping the health system free for those who need it,” Health Minister Andrew Little said.
“But we need medicines for those who do get sick, which is why I am very pleased that the national pharmaceuticals-buying agency Pharmac has secured supplies of another drug shown to work against the COVID-19 virus.
“Baricitinib is the fifth drug Pharmac has secured, and sits alongside remdesivir, tocilizumab, molnupiravir and Ronapreve as treatments doctors can turn to for people with a range of COVID-19 symptoms.
“Like tocilizumab, baricitinib can be used to treat patients who are very sick, as it reduces the severity of symptoms and cuts time in hospital and reduces the likelihood of death.
“Pharmac expects to receive 500 doses of baricitinib this month, which is important because there is a global shortage of tocilizumab and this gives clinicians another option,” Andrew Little said.
Money for all five medicines will come from the Government’s COVID-19 fund. Baricitinib has yet to be approved by Medsafe for use against COVID-19, but clinicians will be able to use it straight away under Section 25 of the Medicines Act.
备注和负责声明
未经书面许可，保留所有权利，不得使用任何部分或完整的文章或照片。本号转载的文章都已注明出处，如对版权有任何疑问，请在第一时间发送邮件给本号， bbcc1223@126.com我们将在收到后第一时间进行删除。
若喜欢作品的可以点击“在看”，这样有机会分享给更多朋友。要是再点击“喜欢作品”，那将对我们鼓舞更大。
本号致力于好文推送，并对文中观点保持中立，所发内容仅供学习、交流。版权归原作者或机构所有，部分文章推送时未能查实原作者，在这里对你们表示深深的敬意。若涉及版权问题，麻烦请留言联系删除